Aptorum Group Ltd Class A is a biotechnology business based in the US. Aptorum Group Ltd Class A shares (APM) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.73 – a decrease of 33.55% over the previous week. Aptorum Group Ltd Class A employs 3 staff and has a trailing 12-month revenue of around $431,378.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.73 |
|---|---|
| 52-week range | $0.64 - $11.95 |
| 50-day moving average | $1.89 |
| 200-day moving average | $3.88 |
| Wall St. target price | $80.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.62 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.731 from 2024-11-19
| 1 week (2024-11-13) | -39.08% |
|---|---|
| 1 month (2024-10-18) | -57.25% |
| 3 months (2024-08-20) | -75.71% |
| 6 months (2024-05-20) | -84.87% |
| 1 year (2023-11-20) | -50.94% |
|---|---|
| 2 years (2022-11-18) | -88.40% |
| 3 years (2021-11-19) | 21.4 |
| 5 years (2019-11-20) | 157.7 |
| Revenue TTM | $431,378 |
|---|---|
| Gross profit TTM | $81,854 |
| Return on assets TTM | -32.3% |
| Return on equity TTM | -37.4% |
| Profit margin | 0% |
| Book value | $4.80 |
| Market Capitalization | $6 million |
TTM: trailing 12 months
We're not expecting Aptorum Group Ltd Class A to pay a dividend over the next 12 months.
Aptorum Group Ltd Class A's shares were split on a 1:10 basis on 22 January 2023 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aptorum Group Ltd Class A shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Aptorum Group Ltd Class A shares which in turn could have impacted Aptorum Group Ltd Class A's share price.
Over the last 12 months, Aptorum Group Ltd Class A's shares have ranged in value from as little as $0.6357 up to $11.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aptorum Group Ltd Class A's is 1.3. This would suggest that Aptorum Group Ltd Class A's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Aptorum Group Limited, through its subsidiaries, operates as a clinical stage biopharmaceutical company that engages in the discovery, development, and commercialization of therapeutic products for the treatment of oncology and infectious diseases. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; ALS-1 to treat viral infections caused by influenza virus A; and ALS-2/3 for the treatment of gram+ve bacterial infections. The company is also developing RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, and other disease areas. In addition, it is involved in the operation of medical clinics.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.